Because treatment‐related hyperglycemia occurred only among recipients of AKT, pan‐PI3k, and PI3K‐alpha targeting inhibitors, analysis of risk factors was restricted to those patients (n = 349). This evidence concerns the gene AKT1 and Hyperglycemia.